Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib

on behalf of the Okayama Liver Cancer Group

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background and Aim: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one-time measurements before treatment. Methods: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin-2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin-2 at the time of progressive disease was a marker of short post-progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression-free survival except the presence of hepatitis B virus surface antigen. Conclusions: Predictions of overall survival and post-progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin-2, in patients with HCC treated with sorafenib.

Original languageEnglish
Pages (from-to)1081-1087
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume34
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • HCC
  • angiopoietin-2
  • proangiogenic cytokines
  • sorafenib

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib'. Together they form a unique fingerprint.

Cite this